Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06039709
Other study ID # HSR230064
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 31, 2024
Est. completion date June 2026

Study information

Verified date February 2024
Source University of Virginia
Contact Zachary Sturgill
Phone 434-243-9986
Email FFM7RC@uvahealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. Focused ultrasound (FUS) can be used to non-invasively destroy tumor tissue while preserving normal tissue. When FUS is combined with 5-ALA, this combinatorial approach is called sonodynamic therapy (SDT), and this investigational therapy is being tested for its ability to cause damage to GBM cells. SDT will take place prior to surgery for recurrent GBM.


Description:

The combination of 5-ALA (Gleolan) and LIFU is collectively known as sonodynamic therapy (SDT). SDT is an investigational therapy that will be administered 1-3 weeks before surgery for recurrent GBM. Researchers seek to determine the safety and feasibility of this therapy as well as measure its effectiveness to elicit tumor-cell death. All participants are expected to stay overnight in the hospital following administration of SDT to monitor for adverse events.


Recruitment information / eligibility

Status Recruiting
Enrollment 11
Est. completion date June 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Disease status and Disease Parameters: - Suspected recurrent glioblastoma that is clearly measurable based on the modified Response Assessment in Neuro-Oncology (RANO) criteria - The tumor lesion needs to comprise at least 1 contrast-enhancing lesion with a volume of = 6 cm3 and = 20 cm3 of targeted treatment area - Tumor tissue to be treated is in a surgically accessible brain region for resection - The brain tumor to be treated must be in the treatment envelope of the NaviFUS system (30 mm to 80 mm from the inner skull table) - Recurrence will be assessed by imaging and confirmed by consensus at tumor board 2. Men or women between the ages of 18-80 years of age at the time of consent 3. No contraindication to repeat brain surgery 4. Karnofsky Performance Score of 70-100 5. Able to undergo an MRI with contrast 6. Able to swallow oral medications 7. Willingness and ability to comply with scheduled visits, treatment plans, lifestyle considerations, laboratory tests, and other procedures. 8. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable). 9. Participants who received prior chemotherapy, radiation therapy, immunotherapy, and/or another investigational therapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade =1 or baseline) from the acute effects of the therapy or therapies) except for residual alopecia or Grade 2 peripheral neuropathy prior to registration. 10. Has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility): Hematological - Absolute neutrophil count (ANC) =1000/mm3 - Platelets = 100,000/mm3 - Hemoglobin = 11 g/dL for women and = 12 g/dL for men Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. - INR = 1.4 Renal & Hepatic - Creatinine clearance CrCl = 60 mL/min/1.73 m2 as estimated by the Cockcroft-Gault (C-G) equation. If estimated CrCl is abnormal, accurate measurement should be obtained by 24- hour CrCl. - Bilirubin = 1.5 x ULN (except in patients with Gilbert's disease, where bilirubin to 2.0x ULN is allowed). - AST and ALT = 3 x ULN - Alkaline phosphatase = 3 x ULN - GGT = 3 x ULN - Estimated glomerular filtration rate =30mL/min/1.73m2 Exclusion Criteria: 1. Known sensitivity or allergy to 5-ALA 2. Simultaneous use of other potentially phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) 3. Diagnosis of porphyria 4. Hypersensitivity against porphyrins 5. Pregnancy 6. Significant cardiac disease or coagulopathy 7. Herniation / intractable seizure / other clinical indications requiring urgent resection 8. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C (for example, hepatitis B surface antigen positive) 9. Have had a recent (=3 months prior to registration) transient ischemic attack or stroke 10. Significant vascular disease (e.g. aortic aneurysm) 11. Evidence of bleeding diathesis or coagulopathy 12. Need for systemic anticoagulation which cannot be held for 7 days prior to SDT 13. Unstable angina and/or congestive heart failure (NYH Class III or Class IV; see section 13.2) within 6 months prior to registration 14. Severe hypertension (systolic = 180 mm Hg; diastolic = 120 mm Hg) despite anti-hypertensive medications 15. Transmural myocardial infarction within 6 months prior to registration 16. Serious and inadequately controlled cardiac arrhythmia 17. Acute exacerbation of chronic obstructive pulmonary disease 18. Has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study 19. Treatment with another investigational drug or investigational procedure within 30 days prior to registration or within 5 half-lives of the investigational product, whichever is longer 20. Brain edema and/or mass effect that causes midline shift of more than 15 mm 21. Evidence of recent (within 30 days prior to registration) intracranial hemorrhage 22. Calcifications or metallic implanted objects in the focused ultrasound sonication path 23. Scalp atrophy or scars at the expected location of transducer 24. Cerebral or systemic vasculopathy 25. Need for or currently on dialysis 26. Respiratory: chronic pulmonary disorders (e.g., severe emphysema, COPD, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area). 27. Receipt of radiotherapy =21 days prior to registration 28. Receipt of chemotherapy = 21 days prior to registration 29. Prior treatment with sonodynamic therapy 30. Concurrent use of Optune device 31. Concurrent use of supplements or medications with substantial antioxidant effects (including sulfhydryl-containing medications such as captopril or supplements such as N-acetylcysteine, or high doses of vitamins with antioxidant activity such as C or E) 32. Known sensitivity to gadolinium

Study Design


Intervention

Combination Product:
5-ALA and Low-Intensity Focused Ultrasound (SDT)
5-ALA (20mg/kg orally) given ~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.

Locations

Country Name City State
United States University of Virginia Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
Shayan Moosa, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events Per NCI Common Terminology Criteria for Adverse Events v5.0 From informed consent through 30 days after study intervention is complete
Primary Severity of adverse events Per NCI Common Terminology Criteria for Adverse Events v5.0 From informed consent through 30 days after study intervention is complete
Primary Incidence of intracranial hemorrhage and/or worsening of edema On post-SDT MRIs From day after SDT (day 1) up to the time of surgery (day 7-day 21)
Primary Extent of targeted tumor area receiving FUS Use of NaviFUS system to target a maximum of 50% of the tumor volume of one contiguous lesion Day 0
Primary Ability to have participants undergo planned surgery without delay A delay is defined as more than 3 weeks after SDT within 3 weeks following SDT
Secondary Response of target tissue following SDT on imaging Via MRI w/ use of modified Response Assessment in Neuro-Oncology (RANO) criteria From day after SDT (day 1) up to 100 days after intervention is completed
Secondary Histologic tumor devitalization Evaluating cell fate and cell death via histologic samples after GBM resection Day 7-Day 21
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Recruiting NCT06059690 - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Phase 1/Phase 2
Recruiting NCT04116411 - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Phase 2
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Completed NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Recruiting NCT01923922 - CT Perfusion in the Prognostication of Cerebral High Grade Glioma N/A
Completed NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma Phase 1
Suspended NCT01386710 - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Phase 1/Phase 2
Completed NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. Phase 1/Phase 2
Completed NCT01402063 - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Phase 2
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Terminated NCT00990496 - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) Phase 1
Completed NCT00402116 - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase 1/Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Recruiting NCT05366179 - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc Phase 1